Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS)

Arthritis Research and Therapy

Volumn 13, Issue 1, 2011, Pages

  Kuemmerle Deschner, Jasmin B ^a   Ramos, Eduardo ^b   Blank, Norbert ^c   Roesler, Joachim ^d   Felix, Sandra D ^e   Jung, Thomas ^e   Stricker, Kirstin ^e   Chakraborty, Abhijit ^f   Tannenbaum, Stacey ^e   Wright, Andrew M ^e   Rordorf, Christiane ^e  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^d UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^e NOVARTIS PHARMA AG   (Switzerland)

^f NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CANAKINUMAB; SERUM AMYLOID A; IMMUNOLOGIC FACTOR; INTERLEUKIN 1BETA; MONOCLONAL ANTIBODY;

ACNE; ADOLESCENT; ADULT; AGED; ARTICLE; BODY WEIGHT; CHILD; CINCA SYNDROME; CLINICAL ARTICLE; CONTROLLED STUDY; COUGHING; DIARRHEA; DISEASE ACTIVITY; DRUG EFFICACY; FEMALE; HUMAN; MALE; PATIENT SAFETY; PHARYNGITIS; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; RASH; RELAPSE; RHINITIS; RHINOPHARYNGITIS; SCHOOL CHILD; SLEEP DISORDER; UPPER RESPIRATORY TRACT INFECTION; VERTIGO; VOMITING; CLINICAL TRIAL; DRUG ANTAGONISM;

ADOLESCENT; ANTIBODIES, MONOCLONAL; CHILD; CHILD, PRESCHOOL; CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES; HUMANS; IMMUNOLOGIC FACTORS; INTERLEUKIN-1BETA;

EID: 79952053673     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3266     Document Type: Article

References (29)

1. Hoffman HM, Mueller JL, Broide DH, Wanderer AA, Kolodner RD. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet 2001, 29:301-305. 10.1038/ng756, 11687797.
2. Cinca syndrome. , http://www.orpha.net/data/patho/GB/uk-cinca.pdf
3. Farasat S, Aksentijevich I, Toro JR. Autoinflammatory diseases: clinical and genetic advances. Arch Dermatol 2008, 144:392-402. 10.1001/archderm.144.3.392, 18347298.
4. Glaser RL, Goldbach-Mansky R. The spectrum of monogenic autoinflammatory syndromes: understanding disease mechanisms and use of targeted therapies. Curr Allergy Asthma Rep 2008, 8:288-298. 10.1007/s11882-008-0047-1, 2735099, 18606080.
5. Touitou I, Koné-Paut I. Autoinflammtory diseases. Best Pract Res Clin Rheumatol 2008, 22:811-829. 10.1016/j.berh.2008.08.009, 19028365.
6. Aganna E, Martinon F, Hawkins PN, Ross JB, Swan DC, Booth DR, Lachmann HJ, Bybee A, Gaudet R, Woo P, Feighery C, Cotter FE, Thome M, Hitman GA, Tschopp J, McDermott MF. Association of mutations in the NALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis. Arthritis Rheum 2002, 46:2445-2452. 10.1002/art.10509, 12355493.
7. Dode C, Le Du N, Cuisset L, Letourneur F, Berthelot JM, Vaudour G, Meyrier A, Watts RA, Scott DG, Nicholls A, Granel B, Frances C, Garcier F, Edery P, Boulinguez S, Domergues JP, Delpech M, Grateau G. New mutations of CIAS1 that are responsible for Muckle-Wells syndrome and familial cold urticaria: a novel mutation underlies both syndromes. Am J Hum Genet 2002, 70:1498-1506. 10.1086/340786, 379138, 11992256.
8. Dinarello CA. The many worlds of reducing interleukin-1. Arthritis Rheum 2005, 52:1960-1967. 10.1002/art.21107, 15986340.
9. Sutterwala FS, Ogura Y, Szczepanik M, Lara-Tejero M, Lichtenberger GS, Grant EP, Bertin J, Coyle AJ, Galan JE, Askenase PW, Flavell RA. Critical role for NALP3/CIAS1/Cryopyrin in innate and adaptive immunity through its regulation of caspase-1. Immunity 2006, 24:317-327. 10.1016/j.immuni.2006.02.004, 16546100.
10. Goldbach-Mansky R, Dailey NJ, Canna SW, Gelabert A, Jones J, Rubin BI, Kim HJ, Brewer C, Zalewski C, Wiggs E, Hill S, Turner ML, Karp BI, Aksentijevich I, Pucino F, Penzak SR, Haverkamp MH, Stein L, Adams BS, Moore TL, Fuhlbrigge RC, Shaham B, Jarvis JN, O'Neil K, Vehe RK, Beitz LO, Gardner G, Hannan WP, Warren RW, Horn W, et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med 2006, 355:581-592. 10.1056/NEJMoa055137, 16899778.
11. Hoffman HM, Throne ML, Amar NJ, Sebai M, Kivitz AJ, Kavanaugh A, Weinstein SP, Belomestnov P, Yancopoulos GD, Stahl N, Mellis SJ. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum 2008, 58:2443-2452. 10.1002/art.23687, 18668535.
12. Ramos E, Arostegui JI, Campuzano S, Rius J, Bousono C, Yague J. Positive clinical and biochemical responses to anakinra in a 3-yr-old patient with cryopyrin-associated periodic syndrome (CAPS). Rheumatology (Oxford) 2005, 44:1072-1073. 10.1093/rheumatology/keh652, 15840596.
13. Lachmann HJ, Lowe P, Felix SD, Rordorf C, Leslie K, Madhoo S, Wittkowski H, Bek S, Hartmann N, Bosset S, Hawkins PN, Jung T. In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes. J Exp Med 2009, 206:1029-1036. 10.1084/jem.20082481, 2715040, 19364880.
14. Alten R, Gram H, Joosten LA, van den Berg WB, Sieper J, Wassenberg S, Burmester G, van Riel P, Diaz-Lorente M, Bruin GJ, Woodworth TG, Rordorf C, Batard Y, Wright AM, Jung T. The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis. Arthritis Res Ther 2008, 10:R67. 10.1186/ar2438, 2483458, 18534016.
15. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, Leslie KS, Hachulla E, Quartier P, Gitton X, Widmer A, Patel N, Hawkins PN. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 2009, 360:2416-2425. 10.1056/NEJMoa0810787, 19494217.
16. Mire-Sluis AR, Barrett YC, Devanarayan V, Koren E, Liu H, Maia M, Parish T, Scott G, Shankar G, Shores E, Swanson SJ, Taniguchi G, Wierda D, Zuckerman LA. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods 2004, 289:1-16. 10.1016/j.jim.2004.06.002, 15251407.
17. Duchateau L, Janssen PP. The Frailty Model. 2008, New York: Springer.
18. Lachmann HJ, Tannenbaum S, Chakraborty A, Preiss R, Hawkins PN. Pharmacokinetics (PK) of canakinumab (ACZ885, a fully human anti-IL-1beta monoclonal antibody) in cryopyrin-associated periodic fever syndrome (CAPS) patients [abstract]. Ann Rheum Dis 2009, 68:196. 10.1136/ard.2007.086009, 18385276.
19. Burger D, Dayer JM, Palmer G, Gabay C. Is IL-1 a good therapeutic target in the treatment of arthritis?. Best Pract Res Clin Rheumatol 2006, 20:879-896. 10.1016/j.berh.2006.06.004, 16980212.
20. Gillespie J, Mathews R, McDermott MF. Rilonacept in the management of cryopyrin-associated periodic syndromes (CAPS). J Inflamm Res 2010, 3:1-8.
21. Porksen G, Lohse P, Rosen-Wolff A, Heyden S, Forster T, Wendisch J, Heubner G, Bernuth H, Sallmann S, Gahr M, Roesler J. Periodic fever, mild arthralgias, and reversible moderate and severe organ inflammation associated with the V198M mutation in the CIAS1 gene in three German patients--expanding phenotype of CIAS1 related autoinflammatory syndrome. Eur J Haematol 2004, 73:123-127. 10.1111/j.1600-0609.2004.00270.x, 15245511.
22. Touitou I, Perez C, Dumont B, Federici L, Jorgensen C. Refractory auto-inflammatory syndrome associated with digenic transmission of low-penetrance tumour necrosis factor receptor-associated periodic syndrome and cryopyrin-associated periodic syndrome mutations. Ann Rheum Dis 2006, 65:1530-1531. 10.1136/ard.2006.054312, 1798361, 17038455.
23. Rosen-Wolff A, Quietzsch J, Schroder H, Lehmann R, Gahr M, Roesler J. Two German CINCA (NOMID) patients with different clinical severity and response to anti-inflammatory treatment. Eur J Haematol 2003, 71:215-219. 10.1034/j.1600-0609.2003.00109.x, 12930324.
24. Aksentijevich I, Putnam DC, Remmers EF, Mueller JL, Le J, Kolodner RD, Moak Z, Chuang M, Austin F, Goldbach-Mansky R, Hoffman HM, Kastner DL. The clinical continuum of cryopyrinopathies: novel CIAS1 mutations in North American patients and a new cryopyrin model. Arthritis Rheum 2007, 56:1273-1285. 10.1002/art.22491, 17393462.
25. Lachmann HJ, Goodman HJ, Gilbertson JA, Gallimore JR, Sabin CA, Gillmore JD, Hawkins PN. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007, 356:2361-2371. 10.1056/NEJMoa070265, 17554117.
26. Ross JB, Finlayson LA, Klotz PJ, Langley RG, Gaudet R, Thompson K, Churchman SM, McDermott MF, Hawkins PN. Use of anakinra (Kineret) in the treatment of familial cold autoinflammatory syndrome with a 16-month follow-up. J Cutan Med Surg 2008, 12:8-16.
27. Ruperto N, Quartier P, Wulffraat P, Woo P, Loy A, Mouy A, Bader-Meunier B, Prakken B, Noseda E, Belleli R, Lecot J, Rordorf C, Martini A. A phase II trial with canakinumab (ACZ885), a new IL-1-beta blocking monoclonal antibody, to evaluate safety and preliminary efficacy in children with systemic juvenile idiopathic arthritis (SJIA) [abstract]. Ann Rheum Dis 2009, 68:170.
28. Committee for medicinal products for human use: Summary of positive opinion for Ilaris. , http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/001109/WC500059888.pdf
29. cder Drug and Biologic Calendar Year Approvals. , http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/DrugandBiologicApprovalReports/PriorityNDAandBLAApprovals/UCM090995.pdf